Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Crenolanib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 known ✓ | P36888 | 6/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 1.00 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 1.00 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | ULK1 | O75385 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | LATS1 | O95835 | 1/20 | 1.00 |
| ▸ | PAK4 | O96013 | 1/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | CDK1 | P06493 | 1/20 | 1.00 |
| ▸ | APRT | P07741 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | PHKG2 | P15735 | 1/20 | 1.00 |
| ▸ | NQO2 | P16083 | 1/20 | 1.00 |
| ▸ | FECH | P22830 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Crenolanib SCHEMBL29350134 | 1.00 | FLT3 (1.00) | FLT3IRAK4GAKRIPK2ULK1 | |
| Crenolanib SCHEMBL29352568 | 1.00 | FLT3 (1.00) | FLT3IRAK4GAKRIPK2ULK1 | |
| Crenolanib SCHEMBL30002138 | 1.00 | FLT3 (1.00) | FLT3IRAK4GAKRIPK2ULK1 | |
| SCHEMBL22567082 | 0.93 | IRAK4 (0.86) | FLT3IRAK4GAKRIPK2ULK1 | |
| Crenolanib SCHEMBL29361948 | 0.92 | FLT3 (0.85) | FLT3IRAK4GAKRIPK2ULK1 | |
| Crenolanib SCHEMBL4681285 | 0.92 | FLT3 (0.85) | FLT3IRAK4GAKRIPK2ULK1 | |
| Crenolanib SCHEMBL29352554 | 0.92 | FLT3 (0.85) | FLT3IRAK4GAKRIPK2ULK1 | |
| SCHEMBL5662568 | 0.92 | IRAK4 (0.85) | FLT3IRAK4GAKRIPK2ULK1 | |
| SCHEMBL30775111 | 0.92 | FLT3 (0.85) | FLT3IRAK4GAKRIPK2ULK1 | |
| SCHEMBL27030604 | 0.92 | FLT3 (0.85) | FLT3IRAK4GAKRIPK2ULK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107382984-B | Preparation method of medicine for treating leukemia | 扬州市三药制药有限公司 | 2020-07-10 | — | — | CN | claimed |
| EP-1594858-B1 | NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | PFIZER PROD INC (US) | 2009-10-14 | — | — | EP | claimed |
| EP-1641780-B1 | PROCESSES FOR THE PREPARATION OF 1- [(BENZOIMIDAZOLE-1YL) QUINOLIN-8-YL] PIPERIDIN-4-YLAMINE DERIVATIVES | PFIZER PROD INC (US) | 2008-11-12 | — | — | EP | claimed |
| JP-2007516168-A | — | — | 2007-06-21 | — | — | JP | claimed |
| US-7183414-B2 | Processes for the preparation of benzoimidazole derivatives | PFIZER INC (US) | 2007-02-27 | — | — | US | claimed |
| US-7071337-B2 | Benzoimidazole derivatives useful as antiproliferative agents | PFIZER INC (US) | 2006-07-04 | — | — | US | claimed |
| EP-1641780-A1 | PROCESSES FOR THE PREPARATION OF 1- [(BENZOIMIDAZOLE-1YL) QUINOLIN-8-YL] PIPERIDIN-4-YLAMINE DERIVATIVES | Pfizer Products Incorporated (US) | 2006-04-05 | — | — | EP | claimed |
| EP-1594858-A2 | NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | Pfizer Products Inc. (US) | 2005-11-16 | — | — | EP | claimed |
| US-20050124599-A1 | Novel benzoimidazole derivatives useful as antiproliferative agents | PFIZER INC. | 2005-06-09 | — | — | US | claimed |
| US-20050020625-A1 | Processes for the preparation of benzoimidazole derivatives | PFIZER INC | 2005-01-27 | — | — | US | claimed |
| WO-2004113322-A1 | PROCESSES FOR THE PREPARATION OF 1-[(BENZOIMIDAZOLE-1YL) QUINOLIN-8-YL] PIPERIDIN-4-YLAMINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2004-12-29 | — | — | WO | claimed |
| WO-2004020431-A2 | NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | PFIZER PRODUCTS INC. (US) | 2004-03-11 | — | — | WO | claimed |
| US-20250223630-A1 | IDENTIFYING DISEASE-CAUSING HUMAN DDX41 GENETIC VARIANTS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2025-07-10 | — | — | US | disclosed |
| US-20240277636-A1 | COMBINATION COMPRISING AT LEAST ONE SEROTONIN REUPTAKE INHIBITOR AND AT LEAST ONE STIMULATOR OF POTASSIUM-CHLORIDE COTRANSPORTER TYPE 2 AND ITS MEDICAL USE | UNIVERSITé LAVAL (CA) | 2024-08-22 | — | — | US | disclosed |
| CN-117897147-A | Combination comprising at least one serotonin reuptake inhibitor and at least one potassium chloride type 2 cotransporter stimulator and medical use thereof | 波尔多大学 | 2024-04-16 | — | — | CN | disclosed |
| US-20240102081-A1 | IDENTIFYING DISEASE-CAUSING HUMAN DDX41 GENETIC VARIANTS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2024-03-28 | — | — | US | disclosed |
| US-20050124599-A1 | Novel benzoimidazole derivatives useful as antiproliferative agents | PFIZER INC. | 2005-06-09 | — | — | US | disclosed |
| US-20050020625-A1 | Processes for the preparation of benzoimidazole derivatives | PFIZER INC | 2005-01-27 | — | — | US | disclosed |
| WO-2004113322-A1 | PROCESSES FOR THE PREPARATION OF 1-[(BENZOIMIDAZOLE-1YL) QUINOLIN-8-YL] PIPERIDIN-4-YLAMINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2004-12-29 | — | — | WO | disclosed |
| WO-2004020431-A2 | NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | PFIZER PRODUCTS INC. (US) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124599-A1 | Novel benzoimidazole derivatives useful as antiproliferative agents | CCNI, CCNT1, CCNA1 | FLT3 297/4885PDGFRB 1621/4885PDGFRA 1234/4885 |
| US-20050020625-A1 | Processes for the preparation of benzoimidazole derivatives | CCNI, CCNT1, CCNE1 | FLT3 567/4885PDGFRB 1909/4885PDGFRA 1486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.